HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $57

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $52 to $57.